The aggressive peripheral T‐cell lymphomas: 2012 update on diagnosis, risk stratification, and management
暂无分享,去创建一个
[1] R. Suzuki,et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] C. Civin,et al. FLT3-ITD Knock-in Impairs Hematopoietic Stem Cell Quiescence/Homeostasis, Leading to a Myeloproliferative Neoplasm , 2011 .
[3] R. Advani,et al. Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update , 2011 .
[4] I. Lossos,et al. Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL) , 2011 .
[5] B. Nathwani,et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. , 2011, Blood.
[6] R. Champlin,et al. Stem-cell transplantation in T-cell non-Hodgkin's lymphomas. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] S. Steinberg,et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. , 2011, Blood.
[8] A. Zelenetz,et al. FDG-PET in the staging and prognosis of T-cell lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] K. Savage,et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Houot,et al. 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] C. Messa,et al. Crizotinib in anaplastic large-cell lymphoma. , 2011, The New England journal of medicine.
[12] Y. Ko,et al. The Efficacy of Bortezomib-CHOP In Patients with Advanced Stage T or NK/T Cell Lymphomas: The Results of Multicenter Phase II Study. , 2010 .
[13] J. Delabie,et al. Favorable Outcome In ALK-Negative Anaplastic Large-Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT): a Prospective Study by the Nordic Lymphoma Group (NLG-T-01) , 2010 .
[14] F. Russo,et al. Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as First-Line Treatment In High-Risk Peripheral T-Cell/NK Lymphomas: A Phase II Trial. , 2010 .
[15] W. Chan,et al. Phase I/II Study of Dasatinib In Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) , 2010 .
[16] A. Neri,et al. In Vitro and In Vivo Evidences of Osteocyte Involvement In Myeloma-Induced Osteolysis , 2010 .
[17] A. Rosenwald,et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. , 2010, Blood.
[18] T. Reiman,et al. Interim report of a phase 2 clinical trial of lenalidomide for T‐cell non‐Hodgkin lymphoma , 2010, Cancer.
[19] L. Pace,et al. Assessment of metabolic activity by PET‐CT with F‐18‐FDG in patients with T‐cell lymphoma , 2010, British journal of haematology.
[20] A. Attarbaschi,et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] R. Advani,et al. Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial. , 2010 .
[22] P. Gaulard,et al. Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphoma: Results of the phase II RAIL trial--A prospective study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 2010 .
[23] S. Proctor,et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. , 2010, Blood.
[24] T. Tsuzuki,et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] D. Patterson,et al. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review. , 2010, Clinical lymphoma, myeloma & leukemia.
[26] P. Gaulard,et al. Advances in the understanding and management of angioimmunoblastic T‐cell lymphoma , 2010, British journal of haematology.
[27] W. Chan,et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. , 2010, Blood.
[28] Patrick Lutz,et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] N. Schmitz,et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] S. Verstovsek,et al. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] A. Feldman,et al. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas , 2008, Leukemia.
[32] D. de Jong,et al. Anaplastic large-cell lymphoma in women with breast implants. , 2008, JAMA.
[33] D. Weisenburger,et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Stefano A Pileri,et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. , 2008, Blood.
[35] Pek-Lan Khong,et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies , 2008, Annals of Hematology.
[36] R. Brezinschek,et al. Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] P. Gaulard,et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. , 2008, Blood.
[38] P. Marlton,et al. Post‐transplant hepatosplenic T‐cell lymphoma successfully treated with hyperCVAD regimen , 2008, American journal of hematology.
[39] D. Sahani,et al. Case records of the Massachusetts General Hospital. Case 8-2008. A 33-year-old man with fever, abdominal pain, and pancytopenia after renal transplantation. , 2008, The New England journal of medicine.
[40] D. A. Bujanda. Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab , 2008 .
[41] N. Schmitz,et al. High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome—Lymphoma Working Party of the European Group for Blood and Marrow Transplantation , 2008 .
[42] S. Pileri,et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. , 2007, Blood.
[43] K. Ohtomo,et al. FDG-PET in T-cell and NK-cell neoplasms. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[44] Christian Gisselbrecht,et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. , 2007, Blood.
[45] R. Gascoyne,et al. Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. , 2007, Gastroenterology.
[46] Y. Yamashita,et al. Hepatosplenic αβ T-cell lymphoma successfully treated with allogeneic bone marrow transplantation , 2007, Bone Marrow Transplantation.
[47] R. Advani,et al. Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine , 2007, Leukemia & lymphoma.
[48] J. Armitage,et al. F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas , 2007, Leukemia & lymphoma.
[49] Shulian Wang,et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] P. Gaulard,et al. Rituximab in Combination with CHOP Regimen in Angioimmunoblastic T-Cell Lymphoma (AITL). Preliminary Results in 9 Patients Treated in a Single Institution. , 2005 .
[51] I. Bruns,et al. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab , 2005, Leukemia.
[52] Terry L. Smith,et al. Prognostic factors and treatment of patients with T‐cell non‐Hodgkin lymphoma , 2005, Cancer.
[53] W. Au,et al. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. , 2004, Blood.
[54] E. Iannitto,et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. , 2004, Blood.
[55] P. Gaulard,et al. Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients , 2003 .
[56] A. Neugut,et al. Risk of malignancy in patients with celiac disease. , 2003, The American journal of medicine.
[57] H. Müller-Hermelink,et al. Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma. , 2002, The American journal of pathology.
[58] K. Ohshima,et al. L-Asparaginase Induced Durable Remission of Relapsed Nasal NK/T-Cell Lymphoma After Autologous Peripheral Blood Stem Cell Transplantation , 2001, International journal of hematology.
[59] M. Gulley,et al. Hepatosplenic αβ T-cell lyrnphomas: A report of 14 cases and comparison with hepatosplenic γδ T-cell lymphomas , 2001 .
[60] A. Grigg,et al. 2′-Deoxycoformycin for Hepatosplenic γδ T-Cell Lymphoma , 2001 .
[61] D. Wright,et al. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] J. Manning,et al. Nasal-Type T/NK Lymphomas: A Clinicopathologic Study of 13 Cases , 2000, Leukemia & lymphoma.
[63] Y. Kwong,et al. Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations. , 1999, The American journal of pathology.
[64] A. Chott,et al. Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology. , 1998, The American journal of pathology.
[65] D. Weisenburger,et al. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[66] P. Gaulard,et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). , 1998, Blood.
[67] P. Gaulard,et al. Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. , 1997, Blood.
[68] B. Nathwani,et al. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .
[69] J. Diebold,et al. CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. , 1997, Blood.
[70] T. Greiner,et al. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. , 1996, Blood.
[71] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[72] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[73] M. Engelhard,et al. Treatment of Angioimmunoblastic Lymphadenopathy (AILD)-Type T-Cell Lymphoma Using Prednisone with or without the COPBLAM/IMVP-16 Regimen , 1992, Annals of Internal Medicine.
[74] E. Coles,et al. COELIAC DISEASE AND MALIGNANCY , 1983, The Lancet.
[75] P. Isaacson,et al. INTESTINAL LYMPHOMA ASSOCIATED WITH MALABSORPTION , 1978, The Lancet.
[76] M. Yaron,et al. Letter: Levamisole in rheumatoid arthritis. , 1976, Lancet.
[77] K. Lennert,et al. Cytological and functional criteria for the classification of malignant lymphomata. , 1975, The British journal of cancer. Supplement.
[78] H. Abu-Zahra,et al. ANGIO-IMMUNOBLASTIC LYMPHADENOPATHY WITH DYSPROTEINÆMIA , 1974, The Lancet.
[79] R. Lukes,et al. Immunologic characterization of human malignant lymphomas , 1974, Cancer.
[80] G. Frizzera,et al. Angio-immunoblastic lymphadenopathy with dysproteinaemia. , 1974, Lancet.
[81] M Tubiana,et al. Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.